Previous 10 | Next 10 |
NEW YORK, NY / ACCESSWIRE / January 20, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: CapStar Financial Holdings, Inc. (...
NEW YORK, NY / ACCESSWIRE / January 10, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: PGT Innovations, Inc. (NYSE:PGTI)'s ...
NEW YORK, NY / ACCESSWIRE / January 8, 2024 / Juan Monteverde , founder and managing partner of the class action firm Monteverde & Associates PC (the "M&A Class Action Firm"), a national securities firm rated Top 50 in the 2018-2022 ISS Securities Class Action Services Report and he...
NEW YORK, NY / ACCESSWIRE / January 8, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: RayzeBio, Inc. (NASDAQ:RYZB)'s sale ...
2024-01-04 23:40:00 ET Summary AstraZeneca will acquire Chinese cell therapy maker Gracell for up to $1.2 billion, representing an 86% premium to the company’s pre-announcement share price. The U.S. FDA announced an investigation into a potential severe risk of T-cell malig...
NEW YORK, NY / ACCESSWIRE / January 4, 2024 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: RayzeBio, Inc. (NASDAQ:RYZB)'s sale ...
2023-12-31 01:55:00 ET Summary Elpiscience Biopharma forms a $1.7 billion collaboration with Astellas Pharma to develop a bispecific macrophage engager. AstraZeneca acquires Gracell Biotech in a deal worth up to $1.2 billion, including a clinical stage CAR-T therapy. Jinan Qil...
2023-12-27 16:11:16 ET Summary Gracell Biotechnologies has seen a 360% increase in its stock price YTD, with a particular boost since AstraZeneca decided to acquire it for USD $1.2 billion. The acquisition price sounds fair, and the run-up following the announcement leaves little ...
NEW YORK, NY / ACCESSWIRE / December 27, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Rover Group, Inc. (NASDAQ:ROVR)'s...
2023-12-26 13:19:25 ET Gainers: RayzeBio ( RYZB ) +101% . IMAC Holdings ( BACK ) +73% . Bit Brother Limited ( BETS ) +63% . Gracell Biotechnological ( GRCL ) +60% . Volcon ( VLCN ) +54% . Sight Sciences ( SGHT ) +45% ...
News, Short Squeeze, Breakout and More Instantly...
Gracell Biotechnologies Inc. Company Name:
GRCL Stock Symbol:
NASDAQ Market:
Gracell Biotechnologies Inc. Website:
Volcon Inc. (VLCN) is expected to report for Q4 2023 Tenaga Nasional Bhd ADR (TNABY) is expected to report for quarter end 2023-12-31 Hesai Group (HSAI) is expected to report for Q4 2023 Intrusion Inc. (INTZ) is expected to report $-0.14 for Q4 2023 Eliem Therapeutics Inc (ELYM) i...
SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell ...
Gracell Biotechnologies Inc. (NASDAQ: GRCL) is the focus of IBN's latest stock spotlight. The company's shares have moved -0.49% on the day to $10.19. Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of ...